Early Biomarkers in Premanifest Huntington's Disease Gene Carriers: a Pilot Study

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this clinical trial is to investigate if new, early biomarkers of the disease are available in presymptomatic genetic carriers of Huntington\'s diesase compared to healthy subjects. The main questions it aims to answer are: Does functional brain MRI is able to detect early biomarkers of the disease in genetic carriers? Does gait study by a virtual reality device can detect early biomarkers of the disease in genetic carriers? Researchers will compare genetic carriers and healthy subjects to see if new, early biomarkers of the disease can be detected .

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: t
View:

• 1\. For PMGC: HD diagnosis confirmed by genetic testing (CAG triplets ≥36 in HTT gene); Unified Huntington Disease Rating Scale19 Total Motor Score (UHDRS-TMS) ≤ 5; age 18-70 years old. 2. For HC: normal neurological examination; age 18-70 years old.

Locations
Other Locations
France
Grenoble University Hospital
RECRUITING
Grenoble
Contact Information
Primary
Sara Meoni, MD, PhD
smeoni@chu-grenoble.fr
+33 4 76 76 57 91
Time Frame
Start Date: 2025-02-20
Estimated Completion Date: 2026-12
Participants
Target number of participants: 20
Treatments
Experimental: neuroimaging assessment
visual stimulation protocol during functional MRI session
Sponsors
Leads: University Hospital, Grenoble

This content was sourced from clinicaltrials.gov